JPM26: Enanta outlines strategy to lead in RSV therapeutics
At the 44th Annual J.P. Morgan Healthcare Conference, Enanta Pharmaceuticals discussed its respiratory syncytial virus (RSV) portfolio and the need…
At the 44th Annual J.P. Morgan Healthcare Conference, Enanta Pharmaceuticals discussed its respiratory syncytial virus (RSV) portfolio and the need…
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link…
MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new long-lasting infectious disease drug technology to…
The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both…
The Biomedical Advanced Research and Development Authority (BARDA) in the US will support Basilea’s development of a new type of…
The US Government has ordered $56m worth of mpox/smallpox vaccines to bolster public health preparedness, despite wider uncertainty in the…
The European Commission (EC) has approved Gilead’s Yeytuo (lenacapavir) for the prevention of HIV infection, consolidating the injectable drug’s potential…
Moderna has secured approval from Health Canada for Spikevax, its updated Covid-19 mRNA vaccine, which targets the SARS-CoV-2 LP.8.1 variant.…
The US Food and Drug Administration (FDA) has approved the first treatment for recurrent respiratory papillomatosis (RRP), a rare respiratory…
Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being developed for the treatment of complicated…